Portal de investigação
The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally.
Autores da FMUP
Participantes de fora da FMUP
- Van Schooten, TS
- Derks, S
- Jimenez-Marti, E
- Ruiz, E
- Alsina, M
- Molero, C
- Garrido, M
- Riquelme, A
- Caballero, C
- Lezcano, E
- O'Connor, JM
- Esteso, F
- Farres, J
- Mas, JM
- Lordick, F
- Vogt, J
- Cardone, A
- Girvalaki, C
- Cervantes, A
- Fleitas, T
Unidades de investigação
Abstract
Filiações
Filiações não disponíveis
Proyectos asociados
Unravelling Helicobacter pylori strategies to disrupt cell-cell junctions
Investigador Principal: Maria do Céu Fontes Herdeiro Figueiredo
Estudo Clínico Académico (Helicobacter) . 2019
The role of hepatocyte apoptosis markers in predicting the histological and serological activity in steatohepatitis
Investigador Principal: Maria de Fátima Machado Henriques Carneiro
Estudo Clínico Académico . 2021
Immune checkpoint inhibitors for the treatment of gastric cancer
Investigador Principal: Maria do Céu Fontes Herdeiro Figueiredo
Estudo Clínico Académico . 2021
Evaluation of the use of Helicobacter pylori genotypes and gastric microbiota markers to identify individuals at high risk of gastric carcinoma
Investigador Principal: Maria do Céu Fontes Herdeiro Figueiredo
Estudo Clínico Académico . 2021
Gastric Cancer Morphological, Immunophenotypic and molecular heterogeneity
Investigador Principal: Maria de Fátima Machado Henriques Carneiro
Estudo Clínico Académico . 2020
Citar a publicação
Van TS,Derks S,Jimenez E,Carneiro F,Figueiredo C,Ruiz E,Alsina M,Molero C,Garrido M,Riquelme A,Caballero C,Lezcano E,O'Connor JM,Esteso F,Farres J,Mas JM,Lordick F,Vogt J,Cardone A,Girvalaki C,Cervantes A,Fleitas T. The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. BMC Cancer. 2022. 22. (1):IF:3,800. (2).
